Myeloma UK Patient Value Mapping
Myeloma is a complex and debilitating haematological cancer. It is the 17th most common cancer in the UK, accounting for two percent of all new cases (Cancer Research UK, 2013). Recent years have seen improvements in survival as a result of routine use of high- dose therapy, autologous stem cell transplant and the introduction of novel therapies (Osborne et al 2012). Today, one third (33%) of people diagnosed with myeloma in England and Wales survive for ten years or more (Cancer Research UK, 2013).
Although myeloma is sensitive to treatments, there is currently no cure. Current treatments are prolonging remission and improving quality of life for myeloma patients. However, such treatments produce both physiological and psychological side-effects. As such patients are faced with a difficult trade-off of survival and remission rates against side-effects when choosing between treatment options.
The aim of this project was thus to enhance the evidence base around myeloma patient preferences and understand the treatment attributes valued by patients. In particular, what attributes of a treatment (for example side effects) are important to patients and how important is each attribute in the treatment of a patients’ condition.
We presented the research findings at the 22nd Congress of the European Hematology Association in Madrid. For more information, see the conference poster here.
Osborne, T. R., Ramsenthaler, C., Siegert, R. J., Edmonds, P. M., Schey, S. A. and Higginson, I. J. (2012), What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol, 89: 437–457. doi:10.1111/ejh.12012